EQS-News: MediClin AG
/ Key word(s): Conference/Miscellaneous
Offenburg, March 21, 2024
MEDICLIN invites you to the virtual press conference on the financial statements for the year 2023 MEDICLIN (Ticker: MED; WKN 659 510) invites you to the virtual press conference on the financial statements for the year 2023. The event will take place on March 26, 2024 at 11.00 a.m. (CET). The Management Board of MEDICLIN will report on the 2023 financial year, current developments at MEDICLIN and the outlook for 2024 in a webcast. Following the presentation by the Management Board, you will have the opportunity to ask questions. The presentation will be held in German. To participate in the press conference, please register at the following link: MEDICLIN virtual press conference on the financial statements for the year 2023 You will then receive the link to the webcast and the dial-in details for the telephone connection. Please dial in 10 minutes before the start of the event. The replay of the webcast (without the Q&A session) will be available on the MEDICLIN website soon after the press conference. We look forward to your participation. For more information: Investor Relations Ender Gülcan, CIIA, CESGA Head of Investor Relations and Sustainability Phone +49 781/488-326 ender.guelcan@mediclin.de MEDICLIN Aktiengesellschaft Okenstraße 27 77652 Offenburg Germany About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510) MEDICLIN includes 32 clinics, six care facilities and ten medical care centers. The Group has around 8,300 beds/care places and employs around 10,000 people. In a strong network, MEDICLIN offers the patient integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs. MEDICLIN ─ a company of the Asklepios Group
21.03.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | MediClin AG |
Okenstraße 27 | |
77652 Offenburg | |
Germany | |
Phone: | +49 (0)781 488-326 |
Fax: | +49 (0)781 488-184 |
E-mail: | ender.guelcan@mediclin.de |
Internet: | www.mediclin.de |
ISIN: | DE0006595101 |
WKN: | 659510 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1864689 |
End of News | EQS News Service |
|
1864689 21.03.2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.